could diminish. Low c-statistics can be a reflection of low patient level variability or low explanatory power of a model, and therefore, it could be incorrect to suggest that the only potential and necessary solution is to increase the number of variables collected. Evaluating ACS NSQIP on logistic regression analysis and limited model diagnostics, such as the c-statistic alone, overlooks the program's overarching purpose of hospital level assessment and improvement.
Borja-Cacho and colleagues attempted to address an important question of how ACS NSQIP can be used for oncology. We thank the authors for raising the profile of these issues and congratulate them on their work. However, we are concerned that their conclusions might not be justified. Furthermore, some of the shortcomings of the program that are pointed out have been well known and are already targeted for improvements. The new ACS NSQIP platform is customizable and will be able to provide uniquely valuable risk-adjusted oncology-specific outcomes to hospitals.
